Dataset opportunity
Dicentra — Downloadable Data Asset Opportunity
Large downloadable data asset held by Dicentra, usable for Fine Tuning and Pretraining.
Score
67.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
73%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global Pharmacovigilance market was valued at $9.35 billion in 2025, projected to grow at a 14.69% CAGR (source: Fortune Business Insights).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-07-30
Agitazione psicomotoria in emergenza: Fimeuc propone un tavolo tecnico per un protocollo unico nazionale
tecnicaospedaliera.it ↗ - 📰press2026-07-30
Oltre la Brexit: opportunità e sfide del mercato UK per i dispositivi medici
distrettobiomedicale.it ↗ - 📰press2026-07-30
Gemeinsame Begriffe für Gesundheitsdaten aus der Stimme
devicemed.de ↗ - 📰press2026-07-30
MTAA Members Update | 31 July 2026
mtaa.org.au ↗ - 📰press2026-07-23
Intelligence26: AI and the Future of Practice
ranzcr.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Downloadable Data Asset
Modality
Tabular
Sector
healthcare
Volume
Large
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Mixed ownership — GDPR-sensitive (PII review)
Buyer persona
Domain LLM builders & vertical AI startups
Dicentra holds a substantial Tabular data asset derived from its healthcare sector activities, including `inspection_records`, `medical_records`, and `regulatory` documentation from clinical trials and pharmacovigilance. This structured, multi-source dataset is exceptionally well-suited for the Fine-Tuning of large language models for specialized life science applications, such as enhancing drug safety analysis and streamlining regulatory compliance reporting.
The business value is anchored in the global Pharmacovigilance market, which was valued at $9.35 billion in 2025 and is projected to grow at a CAGR of 14.69%. Despite complex access requirements due to multi-party consent for secondary use, highly sensitive PII from clinical trials, and strict regulatory oversight, the high-growth demand for this Downloadable Data Asset makes it a rare and valuable resource for AI buyers seeking a competitive advantage. ⚠ Diligence (valuable data, access to negotiate): Data is primarily generated for life science clients, requiring complex multi-party consent for secondary use.; Highly sensitive health data (PII) involved in clinical trials and pharmacovigilance.; Regulatory constraints from FDA and Health Canada regarding data integrity and reporting. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves the holder possesses proprietary data from its core business in healthcare consulting, specifically around pharmacovigilance and clinical trial support. The dataset contains structured information on adverse event reporting, regulatory processes, and toxicological risk assessments. For vertical AI startups, this is a crucial asset for fine-tuning domain-specific LLMs to automate and improve drug safety monitoring, a key function in a global pharmacovigilance market projected to grow at nearly 15% annually.
See dimension details ↓- Dataset Specificity90
dominant 'downloads', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume94
10 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Fine Tuning
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI buyer demand is high, driven by the significant growth in the Pharmacovigilance market, which is expanding at a 14.69% CAGR as companies increasingly adopt AI to enhance drug safety and regulatory compliance.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength100
5 evidence types, 10 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
ownership=mixed, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus70
surplus=medium, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — Dicentra is a contract research and consulting firm whose core business is providing regulatory and compliance services, which generates valuable clinical trial and product data as a by-product, making it a good target. Issues: The primary issue is determining the ownership of the data generated during client projects (clinical trials, regulatory submissions) and whether Dicentra retai; There is a separate, acquired entity named 'Dicentra Pension Services, LLC' which should not be confused with the target company. [7]; There is also a plant genus named 'Dicentra', which pollutes search results. [5, 8, 9, 11]
- Deep Qualification90
⚠ needs review — Dicentra is a Contract Research Organization (CRO) whose business is providing regulatory and clinical trial services; the data it processes is owned by its clients and highly restricted, making the data asset opportunity non-viable under the current structure. [data is owned by the company's customers; licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
This evidence points to a tabular dataset of professional contacts who have registered to access specialized healthcare regulatory resources, providing a valuable source of industry leads and intent data.
Knowledge base / docs
The holder possesses a knowledge base detailing processes for regulatory compliance and toxicological risk assessment, essential for training AI to understand and automate chemical hazard classification.
Medical records / imaging
This indicates the existence of structured records related to adverse event evaluation, classification, and case reporting, a core component for any AI focused on pharmacovigilance.
Regulatory records
The company generates data from custom biostatistical analyses for Phase I-IV clinical trials, a high-value asset for models predicting trial outcomes or optimizing research protocols.
Inspection reports
This points to documentation detailing the requirements and strategies for gaining market access for healthcare products, useful for AI systems that navigate global regulatory pathways.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Dicentra Downloadable Data — a Large downloadable data asset (Tabular modality) in the healthcare domain. Primary AI use-case: Fine Tuning. Market signal: Global Pharmacovigilance market was valued at $9.35 billion in 2025, projected to grow at a 14.69% CAGR (source: Fortune Business Insights).. Investment score 67.9/100 (confidence 0.73). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Endiatx — Medical Imaging Dataset Opportunity
View opportunity →healthcareAktiia — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareNeocis — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- 5 Mistakes That Drive Buyers Away3 min read
- Why Buy External Data?3 min read
- Buying Data Without Mistakes3 min read